| Eligibility |
Inclusion Criteria:
- Cardiac biopsy or technetium pyrophosphate scintigraphy confirmed patients
- Stage I, II, and early and late stage III in numbers as described , irrespective of EF
or NYHA functional class
- Patients aged 18 -85, both genders and of all races and ethnicities.
- Patients must be competent to give informed consent.
- Patients must be able to have the Biomonitor 3 implanted.
- Amyloid stage I-III patients with existing implantable cardiac devices such as
pacemakers or defibrillators
Exclusion Criteria:
- Significant coronary artery disease > 75% luminal stenosis in at least 1 epicardial
vessel (by cardiac catheterization or coronary computed tomography), or history of
myocardial infarction or coronary revascularization.
- Congenital heart disease.
- Pregnant patients
- Patients whose heart failure is felt to be secondary to primary valvular disease
(>moderate/severe mitral regurgitation), uncorrected thyroid disease, obstructive or
hypertrophic cardiomyopathy, pericardial disease or a systemic illness.
- Absolute contraindications to cardiac MRI (such as renal failure with GFR<30%).
- Unwilling or unable to provide informed consent.
- Patients with other life threatening diseases that would likely decrease their life
expectancy over the next four years.
- Patients who are post cardiac transplant.
- Difficulty to attend the follow-up schedule due to a history of medical noncompliance,
difficulty, or unwillingness to return to the study center for follow up.
- Evidence of ongoing bacteremia or sepsis preventing implantation of a device
- Unwilling or able to have the Biomonitor 3 interrogated
|
